logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10077430 B1

PDFFull Text
Date of Patent:
Sep. 18, 2018

Filed:

Nov. 21, 2013

Recombinant adenovirus with increased safety and anticancer activities, and use thereof

Applicant:

National Cancer Center, Gyeonggi-do, KR;

Inventors:

Sang Jin Lee, Gyeonggi-do, KR;

Yun-Hee Kim, Seoul, KR;

In-Hoo Kim, Gyeonggi-do, KR;

Seong-Wook Lee, Gyeonggi-do, KR;

Jin-Sook Jeong, Busan, KR;

Sang Young Han, Busan, KR;

Assignee:

NATIONAL CANCER CENTER, Gyeonggi-Do, KR;

Attorney:

SIMI Law Group, P.C.

Primary Examiner:

Maria Marvich

Int. Cl.
CPC ...
C12N 15/861 (2006.01); C12N 15/113 (2010.01); C12N 15/33 (2006.01); C12N 15/34 (2006.01); C12N 15/52 (2006.01); A61K 48/00 (2006.01); C12N 7/00 (2006.01); A61K 35/761 (2015.01); A61K 38/45 (2006.01); A61K 31/713 (2006.01); G01N 33/574 (2006.01); G01N 33/569 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
C12N 7/00 (2013.01); A61K 31/713 (2013.01); A61K 35/761 (2013.01); A61K 38/45 (2013.01); A61K 48/0066 (2013.01); C12N 15/1135 (2013.01); C12N 15/86 (2013.01); C12Y 207/07049 (2013.01); G01N 33/56983 (2013.01); G01N 33/57438 (2013.01); C12N 2310/1241 (2013.01); C12N 2320/32 (2013.01); C12N 2330/51 (2013.01); C12N 2710/10021 (2013.01); C12N 2710/10032 (2013.01); C12N 2710/10343 (2013.01); C12N 2710/16633 (2013.01); C12N 2810/6018 (2013.01); C12N 2830/008 (2013.01); C12N 2830/42 (2013.01); C12N 2840/445 (2013.01); C12Y 207/01021 (2013.01); G01N 2333/075 (2013.01);
Abstract

The present invention relates to a recombinant adenovirus with increased in-vivo safety, tissue specificity, and anticancer activities, and a use thereof. Specifically, the recombinant adenovirus comprising: a promoter of the liver tissue-specific phosphoenolpyruvate carboxykinase (PEPCK) gene; a trans-splicing ribozyme which is operably linked to the promoter and acts on a cancer-specific gene; a therapeutic gene or a reporter gene which is linked to the 3' exon of the ribozyme; and a serotype 35 fiber knob and a serotype 5 shaft, in which the orf4 gene is deleted from adenovirus E1, E3 and E4 orf1, shows remarkable in-vivo safety, high specificity for a target tissue, and remarkable anticancer effects, and thus can be useful for an anticancer drug or a cancer diagnostic agent as a gene delivery vector.

Find Patent Forward Citations

Loading…